Immunic, Inc. (IMUX) Financials

IMUX Assets vs Liabilities
DateAssetsLiabilities
March 31, 2026 189.7 million 146000
Dec. 31, 2025 24.1 million 30.7 million
Sept. 30, 2025 40.7 million 30.2 million
June 30, 2025 61.4 million 27.5 million

IMUX Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
March 31, 2026 -17.3 million 4.5 million
Dec. 31, 2025 -19.3 million 1.3 million
Sept. 30, 2025 -20.2 million 3.6 million
June 30, 2025 -24.6 million 1.9 million

IMUX Net Income

No data available :(

IMUX Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
March 31, 2026 186.6 million 146000 -
Dec. 31, 2025 15.5 million 107000 107000
Sept. 30, 2025 35.1 million - 126000
June 30, 2025 55.3 million - 979000

IMUX Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
March 31, 2026 30.1 million
Dec. 31, 2025 15.6 million
Sept. 30, 2025 19.4 million
June 30, 2025 13.2 million

IMUX Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
March 31, 2026 2000 25.6 million 7.6 million -
Dec. 31, 2025 11000 19.1 million 4.3 million -
Sept. 30, 2025 67000 20.0 million 6.0 million -
June 30, 2025 36000 21.4 million 5.7 million -

IMUX Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
March 31, 2026 - -
Dec. 31, 2025 - 42000
Sept. 30, 2025 - -
June 30, 2025 - 43000

IMUX

Price: $13.71

52 week price:
5.06
15.77

Earnings Per Share: -4.77 USD

Exchange: NMS

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 562646

Market Capitalization: 127.4 million

Links: